Japan’s Astellas to Acquire U.S. Drugmaker for 5.9 B. Dlrs
12:08 JST, May 1, 2023
Tokyo (Jiji Press)—Japanese drugmaker Astellas Pharma Inc. said Monday that it has agreed to buy U.S. biopharmaceutical startup Iveric Bio Inc. for $5.9 billion in its largest corporate acquisition.
Astellas aims to complete the acquisition of Iveric, which develops ophthalmologic drugs, in July-September following U.S. antitrust and other regulatory screenings.
Astellas will take out bank loans and issue commercial paper to finance the acquisition.
Iveric, listed on the U.S. Nasdaq market, has applied for U.S. Food and Drug Administration approval for an age-related macular degeneration drug that is expected to help maintain or restore vision. The screening is expected to finish in August.
"Business" POPULAR ARTICLE
-
G20 Sees Soft Landing for Global Economy; Leaders Pledge to Resist Protectionism as Trump Calls for Imported Goods Flat Tariff
-
Japan Business Circle Calls for China Resuming Visa-Free Travel; Keizai Doyukai Visit to Country Marks 1st in 8 Years
-
Call Centers Using AI to Address Customer Harassment: NTT and Fujitsu Develop Programs to Improve Employee Interactions, Reduce Turnover
-
Major Start-Up Support Center Station Ai Opens in Nagoya; ¥15.3 Bil. Facility Built to Bring Together Emerging Companies
-
Japan’s Sumitomo Mitsui Offers New Hires Sure Path to U.S., U.K. Branches, with 40% of Bank Revenue Already Coming from Abroad
JN ACCESS RANKING
- Streaming Services Boost Anime Popularity Overseas; Former ‘Geeky’ Interest More Beloved Among Gen Z than 3 Major U.S. Sports
- G20 Sees Soft Landing for Global Economy; Leaders Pledge to Resist Protectionism as Trump Calls for Imported Goods Flat Tariff
- 2024 POLLS: Ruling Camp Likely to Win Lower House Majority
- Chinese Rights Lawyer’s Wife Seeks Support in Japan; Sophie Luo Calls for Beijing to Free Ding Jiaxi, Xu Zhiyong
- Chinese Social Media Still Full of Anti-Japanese Posts 1 Month After Boy’s Fatal Stabbing; Malicious Videos Gain Large Number of Views